What is HC Wainwright’s Forecast for SGMO FY2026 Earnings?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – HC Wainwright cut their FY2026 earnings per share estimates for Sangamo Therapeutics in a report issued on Thursday, April 2nd. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will earn ($0.17) per share for the year, down from their previous forecast of ($0.10). HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q4 2026 earnings at ($0.04) EPS and FY2027 earnings at $0.00 EPS.

A number of other research analysts have also recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sangamo Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen cut Sangamo Therapeutics to a “strong sell” rating in a research note on Saturday, January 31st. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $5.50.

Sangamo Therapeutics Stock Performance

Shares of SGMO stock opened at $0.26 on Tuesday. Sangamo Therapeutics has a 52-week low of $0.21 and a 52-week high of $0.84. The company has a market capitalization of $106.09 million, a PE ratio of -0.58 and a beta of 1.49. The business’s fifty day moving average is $0.38 and its 200 day moving average is $0.46.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Monday, March 30th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.12). Sangamo Therapeutics had a negative return on equity of 1,070.18% and a negative net margin of 310.81%.The business had revenue of $14.23 million during the quarter, compared to analysts’ expectations of $40.25 million.

Institutional Trading of Sangamo Therapeutics

Several large investors have recently modified their holdings of the business. World Investment Advisors grew its stake in shares of Sangamo Therapeutics by 88.5% in the third quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 20,000 shares during the last quarter. R Squared Ltd grew its stake in shares of Sangamo Therapeutics by 22.2% in the fourth quarter. R Squared Ltd now owns 147,191 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 26,732 shares during the last quarter. Golden State Equity Partners grew its stake in shares of Sangamo Therapeutics by 6.9% in the third quarter. Golden State Equity Partners now owns 418,943 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 27,000 shares during the last quarter. Wealth Management Associates Inc. lifted its holdings in Sangamo Therapeutics by 9.1% in the third quarter. Wealth Management Associates Inc. now owns 335,800 shares of the biopharmaceutical company’s stock worth $226,000 after buying an additional 28,000 shares during the period. Finally, Oracle Investment Management Inc. boosted its position in Sangamo Therapeutics by 3.1% during the 4th quarter. Oracle Investment Management Inc. now owns 1,035,742 shares of the biopharmaceutical company’s stock valued at $435,000 after acquiring an additional 31,018 shares in the last quarter. 56.92% of the stock is owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.